Worth reading
43Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
126
¥ million (reduction in operating loss)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Financial results presentationSecond quarter of the fiscal year ending September 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥414 million+102.3%
Operating profit¥-629 million operating loss
Ordinary income¥-516 million ordinary loss
Net income¥-551 millions interim net loss
Gross Profit Margin28.1 %
Selling, general and administrative expenses¥746 million
Full-year earnings forecast
Net Sales
¥943 million
Gross profit
¥202 million
Selling, general and administrative expenses
¥1,656 million
Operating loss
¥-1,454 million
Ordinary loss
¥-1,449 million
Net loss for the period
¥-1,453 million
Revenue from the cell processing business
¥943 million
Revenue from the regenerative medicine products business
¥0 million
Operating loss in the cell processing business
¥-403 million
Operating loss in the regenerative medicine products business
¥-502 million
Corporate expenses
¥-547 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Cell processing business revenue is behind planBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net SalesHigher number of S-DSC® processing cases, lower number of immune cell processing cases, a one-time CDMO technology transfer fee, and lower facility operation and management fee revenue in the value chain business
Operating lossHigher gross profit, cost reductions, and lower research and development expenses, selling expenses, and general and administrative expenses
Ordinary loss¥103 million gain on investment partnership operations and other factors
New initiatives
- Begin accepting ASC contracts during the current fiscal year
- Manufacturing setup toward the start of clinical research on 3D-DCob
- Consultations with the PMDA toward filing a domestic clinical trial notification for MDNT-03
- Alliance activities prompted by regulatory development in Asian countries
- Promote the capture of inbound demand
- Obtain preclinical proof of concept for HSP-105-specific TCR-T cells
- Strengthen intellectual property and submit papers on HLH-CAR-T cells
- Discuss collaborative research toward commercializing MUSCAT-Assay as a cancer risk test
Key KPIsA metric the company considers important as a management benchmark.
- Cumulative number of cell processing cases for specified cell-processed products (immune cells)Approximately 200,000
- Serious accidents0 Engagements
- Medical institutions commissioned to manufacture S-DSC®5 Facility
- MDNT-03 treatment results in IndiaMore than 800
Segment results
Cell Processing Business
Net Sales
¥413 million
Regenerative Medicine Products Business
Profit
¥-177 million segment loss
Year on year against the same period last yearThe year-earlier period recorded a ¥216 million loss
Financial targets
Equity ratio
89.4 %
Actual resultsAs of 31 March 2026
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Second quarter of the fiscal year ending September 2026 |
| Net Sales | ¥414 million (YoY +102.3%) |
| Operating profit | ¥-629 million (operating loss) |
| Ordinary income | ¥-516 million (ordinary loss) |
| Net income | ¥-551 millions (interim net loss) |
| Gross Profit Margin | 28.1 % |
| Selling, general and administrative expenses | ¥746 million |
| Full-year earnings forecast | Net Sales ¥943 million / Gross profit ¥202 million / Selling, general and administrative expenses ¥1,656 million / Operating loss ¥-1,454 million / Ordinary loss ¥-1,449 million / Net loss for the period ¥-1,453 million / Revenue from the cell processing business ¥943 million / Revenue from the regenerative medicine products business ¥0 million / Operating loss in the cell processing business ¥-403 million / Operating loss in the regenerative medicine products business ¥-502 million / Corporate expenses ¥-547 million |
| Self-assessment against the plan | Cell processing business revenue is behind plan |
| Segment results | Cell Processing Business Net Sales ¥413 million / Profit Not disclosed / Year on year against the same period last year Not disclosed / Regenerative Medicine Products Business Net Sales Not disclosed / Profit ¥-177 million (segment loss) / Year on year against the same period last year The year-earlier period recorded a ¥216 million loss |
| Breakdown of Factors Affecting the Change | Net Sales Higher number of S-DSC® processing cases, lower number of immune cell processing cases, a one-time CDMO technology transfer fee, and lower facility operation and management fee revenue in the value chain business / Operating loss Higher gross profit, cost reductions, and lower research and development expenses, selling expenses, and general and administrative expenses / Ordinary loss ¥103 million gain on investment partnership operations and other factors |
| Key KPIs | Indicator name Cumulative number of cell processing cases for specified cell-processed products (immune cells) / Value Approximately 200,000 / Year on year against the same period last year Not disclosed, Indicator name Serious accidents / Value 0 Engagements / Year on year against the same period last year Not disclosed, Indicator name Medical institutions commissioned to manufacture S-DSC® / Value 5 Facility / Year on year against the same period last year Not disclosed, Indicator name MDNT-03 treatment results in India / Value More than 800 / Year on year against the same period last year Not disclosed |
| Financial targets | Equity ratio 89.4 % |
| New initiatives | Begin accepting ASC contracts during the current fiscal year, Manufacturing setup toward the start of clinical research on 3D-DCob, Consultations with the PMDA toward filing a domestic clinical trial notification for MDNT-03, Alliance activities prompted by regulatory development in Asian countries, Promote the capture of inbound demand, Obtain preclinical proof of concept for HSP-105-specific TCR-T cells, Strengthen intellectual property and submit papers on HLH-CAR-T cells, Discuss collaborative research toward commercializing MUSCAT-Assay as a cancer risk test |
Items this document does not state (16)
Operating profit marginResults for the three months of the current quarterProgress against full-year forecastUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Gross profit increased and operating loss narrowed due to a higher number of S-DSC® processing cases, recognition of a one-time technology transfer fee in the CDMO business, a review of the cost allocation method and cost reductions at cell processing facilities, and lower research and development expenses, selling expenses, and general and administrative expenses. Ordinary loss narrowed due in part to a ¥103 million gain on investment partnership operations.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.